Last reviewed · How we verify

NCT04778878: APPS

Assessment of Chemotherapy-induced Peripheral Neurotoxicity Using a Point-of-care Nerve Conduction Study Device

Completed Last updated 24 August 2025
What this trial tests

trial testing Mediracer® NCS in Cancer in 12 participants. Completed in 28 February 2021.

Timeline
1 October 2019
Primary endpoint
28 February 2021
28 February 2021

Quick facts

Lead sponsorOulu University Hospital
StatusCompleted
Study typeOBSERVATIONAL
Enrollment12
Start date1 October 2019
Primary completion28 February 2021
Estimated completion28 February 2021
Sites1 location across Finland

Drugs / interventions tested

Conditions studied

Sponsor

Oulu University Hospital

Who can join

18 and older, any sex, with Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the feasibility of the Mediracer® NCS device in early detection of CIPN in patients receiving potentially neurotoxic substance (vincristine, oxaliplatin or docetaxel) as a part of their chemotherapy regimen.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. Assessment of chemotherapy-induced neurotoxicity using a point-of-care nerve conduction study device.
    Jokimäki A, Iivanainen S, Mikkonen R, Mika K, et al · · 2023 · cited 3× · PMID 35818348 · DOI 10.1002/cnr2.1677

Verify or expand the search:

Other recruiting trials for Cancer

Currently open trials in the same condition.

Other Oulu University Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04778878.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing